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Mild cognitive impairment (MCI) is a subclinical cognitive decline in the elderly that 
increases the risk of conversion to Dementia.  Delaying the onset of conversion from normal 
cognition to MCI has public health relevance by potentially reducing the magnitude of cognitive 
dysfunction related disability.  It has been suggested that cognitive reserve, comprised of IQ and 
behaviors associated with memory facilitation and problem solving, may delay onset of MCI.  
Time to onset of MCI may also be associated with the risk factor of the APOE-4 allele. MCI 
classification criteria is inconsistent across studies, suggesting additional public health need to 
standardize an accurate method of screening.  This study examined the association between 
cognitive reserve, APOE-4, and time to onset of MCI.  Data from the 8 year Gingko Evaluation 
of Memory Study (GEM) clinical trial were used to examine these aims in a sample of n=2,284 
cognitively normal individuals. The GEM MCI classification algorithm was extended over 8 
years to examine normal cognition survival.  Indicators of cognitive reserve were IQ, average 
monthly frequency of cognitive reserve behaviors, and number of different cognitive reserve 
behaviors engaged in each month.  APOE-4 presence was defined as having at least one copy of 
the APOE-4 allele.  N=1,226 (53.68%) individuals remained cognitively normal over the eight 
year followup compared to n=1,058 (46.32%) who developed incident MCI over eight year 
followup.  Incident MCI individuals had significantly higher age (p<0.0001) and education 
(p=0.0320) at entry and were more likely to be male (p=0.0497), Asian/Pacific Islander, Black, 
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or “Other” identified race (p=0.0078).  Incident MCI individuals had significantly lower 
frequency of reading newspapers (p=0.0228) and solving crosswords (p=0.0301), as well as IQ 
(p=0.0002).  Neither the average monthly frequency of cognitive reserve behaviors (p=0.6662) 
nor the number of different cognitive reserve behaviors engaged in each month were 
significantly associated with MCI onset (p=0.7809).  Age (p<0.0001), education (p<0.0001), IQ 
(p<0.0001), and APOE-4 presence (p<0.0001) were significantly associated with time to MCI 
onset in a Cox proportional hazard model adjusted for age, education, IQ, APOE-4 presence, 
cognitive reserve behavior frequency, and number of different cognitive reserve behaviors 
engaged in each month. 
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1.0  BACKGROUND 
A general decline in cognitive and executive function is expected as a product of the 
natural aging process in human beings.  Extremely fast or profound deterioration may instead be 
the result of an underlying progression of neurodegenerative illness.  Clinicians and researchers 
have identified a subclinical state that shows a substantial association with the risk of developing 
age related neurodegenerative illness1, 2, and 3.  This stage known as Mild Cognitive Impairment 
(MCI) is comprised of a mix of symptoms similar to dementia- memory decline, difficulty with 
language, problems with planning and executive function- but at lower levels which are not 
easily diagnosed and do not meet clinical thresholds for dementia1,2,3,4.  The affected individual 
likely has inhibited planning, speed of recall, and may even be aware of slight memory deficits.  
These deficits may go unnoticed and persist for many years before obvious progression to 
clinical dementia occurs5. A potential intervention to prevent an individual’s cognition from 
deteriorating from normal to MCI would theoretically also reduce the number of people who 
progress to clinical Dementia and Alzheimer’s5, 6.  Such an intervention would greatly reduce the 
health related, social, and economic costs that this aging population faces by delaying the onset 
of MCI8.9. 
MCI identification is complex and often unreliable due to inconsistent diagnostic criteria.  
A major source of this unreliability comes from the difficulty in characterizing accurate criteria 
for MCI diagnosis3, 7.9.  Research has shown that within one clinic, estimated frequencies of MCI 
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varied significantly across the same sample of patients (n=676) simply by altering the method of 
assessment. Using one summarized test score yielded an estimate of 84.3% of patients meeting 
MCI criteria, whereas a mixed methods diagnostic approach yielded a much lower estimate of 
39.5% 7.  Other papers support this idea by showing that using a single score testing for 
diminished verbal memory is biased against people with low education10.  This variability in 
sensitivity suggests the need for a more systematic method of identifying MCI. There is also a 
relative lack of studies examining MCI screening methods when adjusting for modifiable 
behaviors such as education14.  These factors suggest a need to more accurately characterize MCI 
and to identify more elements that may potentially modify the progression from normal 
cognition to MCI.    
Past studies have shown that certain behaviors can increase the speed of problem solving 
and facilitate memory formation.  Behaviors such as choosing a cognitively difficult occupation, 
obtaining higher education, and solving puzzles are components of the cognitive reserve 
hypothesis, which postulates that mitigation of cognitive decline can occur as a result of 
participation in activities which stimulate thought11,12,13,14,15,16,17.  This provides evidence to 
suggest that if cognitive reserve is modifiable, an intervention utilizing cognitive reserve to delay 
MCI may be applied to a target population at risk for cognitive decline, such as the elderly11, 12, 
13, and 14.  Another population at risk for MCI may include those who have a genetic pre-
disposition for accelerated cognitive decline, such as individuals carrying the risk allele of 
Apolipoprotein E-4 (APOE-4).  Unlike the other variants of APOE-2 or APOE-3, APOE-4 has 
been shown to be a significant risk factor for dementia and Alzheimer’s disease as well as earlier 
onset Parkinson’s disease based on longitudinal studies17, 18.19,20,21.  The exact mechanism by 
which APOE-4 increases these risks is unknown at the moment, yet population cohort studies 
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note that  E4’s effect size is significantly associated with increasing age, suggesting it may be 
related to MCI dysfunction in the elderly18, 22. 
 It is important in this study to examine if components of cognitive reserve can 
significantly moderate the time to onset of symptoms of MCI.  We aim to 1.) Examine whether 
or not the average monthly participation of modifiable cognitive reserve behaviors and the 
number of different types of cognitive reserve behaviors is inversely related to MCI onset.  
We will also 2.) Examine APOE-4 heterozygous and homozygous genotypes to determine 
whether or not this genetic factor affects time to appearance of MCI.  Lastly, we will 3.) 
Examine if the average monthly participation of modifiable cognitive reserve behaviors 
and the number of different types of cognitive reserve behaviors are significant upon 
adjusting for age at entry, IQ, years of education, and APOE-4 presence. Data from an 8 
year longitudinal study of a subset of individuals from the Gingko Evaluation of Memory Study 
(GEM) were analyzed to determine these aims3 and 23.  The GEM study’s Gingko Biloba 
intervention was determined to be insignificant, therefore the entire sample can be observed free 
of interference23.   
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2.0  METHODS 
2.1.1 Subjects and Procedures 
All participant data were collected as part of the Gingko Evaluation of Memory Study 
(GEM) -a randomized clinical trial investigating the hypothesis that Gingko Biloba 
supplementation may lower incidence of dementia.  Subjects were recruited from the period of 
2000-2002 and followed over a period of eight years.  Details about recruitment locations and 
methods have been published previously26.  Subjects were pre-screened via the Telephone 
Interview for Cognitive Status (TICS) psychological battery and individuals who were 
determined to not have dementia,  not taking Warfarin or Gingko Biloba, and did not have liver 
or kidney issues were invited for full neuropsychological  and physical testing including a blood 
draw23.  Cognition was measured with the Modified Mini-Mental State Examination (3MSE), 
clinical dementia rating (CDR), Alzheimer’s disease assessment-cognitive portion (ADAS-cog), 
and a proprietary neuropsychological battery3 and 23.  Participants who had a CDR of 0, completed 
at least 6 out of 10 GEM neuropsychological tests, and scored in the age by education stratified 
lowest 10th percentile on <2 tests were grouped as “normal”3.  Participants who were determined 
to have undiagnosed dementia were excluded from further participation.  Participants who had a 
CDR of 0.5, completed at least 6 out of 10 GEM neuropsychological tests, and scored in the age 
by education stratified lowest 10th percentile on ≥2 tests were included and grouped as “MCI”3.  
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Subjects were included only if they did not have any pre-existing neurodegenerative disease or 
bleeding/clotting disorder, and did not use cholinesterase inhibitors, Gingko Biloba, Vitamin E, 
or anticoagulants.  Follow up consisted of 6 month checkups involving the 3MSE, CDR, and 
ADAS-cog, with annual examinations including the proprietary neuropsychological battery23.  6 
month checkups showing significant decrease in the 3MSE, CDR, and ADAS-cog necessitated 
inclusion of the proprietary neuropsychological battery, followed by neurological examination 
and imaging if abnormalities remained. The maximum number of visits in the study that any 
participant could achieve was 16.   In 2004, the study design changed to include the full 
neuropsychological battery at each annual visit for every participant regardless of performance 
on the 3MSE, CDR, or ADAS-cog23.  The current study examined the subsample of participants 
without MCI at baseline and followed their cognitive function longitudinally. 
2.1.2 Determining Mild Cognitive Impairment 
Baseline cognition and MCI were determined using a data driven algorithm based on a 
compilation of individually validated test scores3 and 23. Domains tested included verbal memory 
(California Verbal Learning Test), visual memory (24 point modified Rey-Osterrieth figure), 
construction (24 point modified Rey-Osterrieth figure-copy condition and 24 point modified 
WAIS-R Block Design), language (30 item Boston Naming Test and Animal Fluency Test), 
psychomotor Speed/attention (Trail-Making Test A and WAIS-R Digit Span Forward) and 
executive functions (Trail-Making Test B and Stroop color/Word Test)3. A complementary 
CDR-a battery designed to diagnose the presence and severity of dementia symptoms- was also 
utilized.  MCI diagnosis was based upon a global CDR score of 0.5 as well as testing below the 
age by education stratified 10th percentile on 2 or more of the neuropsychological battery tests as 
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previously determined by the Cardiovascular Health Study’s (CHS)3 and 23.  This was also the 
criteria for diagnosing MCI during the current study. 
2.1.3 Defining Cognitive Reserve 
At baseline, the frequency and diversity of everyday behaviors that reflected cognitive 
reserve were measured.  These behaviors (reading a book, reading a newspaper, talking about 
local/national problems with someone, doing crossword puzzles, the ability to use a computer, 
balancing a checkbook, and taking classes to learn a new subject) were obtained using the 
Lifestyle Activity Questionnaire (LAQ) 25.  The subjects were then asked to quantify the average 
monthly time spent on each activity on a Likert scale ranging from 0-“Never/less than once a 
month” to 5-“everyday”.  Based on existing literature suggesting a more easily interpretable 
summary score, 0-5 scores were changed to 0= “not at all”, 1 = “once a month”, 2.5 = “two to 
three times a month”, 4 = “once a week”, 10 = “2 to three times a week”, and 30 = “everyday”25.  
The average frequency of participation in cognitive reserve behaviors was estimated by creating 
a summary score adding the new 30 day scaled scores and dividing by the number of behaviors 
comprising cognitive reserve25.  Diversity of cognitive reserve behaviors was defined as the total 
number of different cognitive reserve behaviors that an individual participated in at least once a 
month25.  Premorbid IQ (National Adult Reading Test-American Version, Ravens Colored 
Progressive Matrices) was collected at baseline as well.  For the current study, these 3 
components (IQ, summary score of the frequency of cognitive reserve behaviors, number of 
different cognitive reserve behaviors engaged in) comprise cognitive reserve.   
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2.1.4 APOE-4 Genotyping 
A blood draw was collected at baseline from the participants and used for laboratory 
analysis, which included the genotyping of the risk allele APOE4.  For the purposes of the 
current study, individuals with genotypes 24, 34(heterozygotes), and 44(homozygotes) will be 
termed “APOE-4 present”.  All other genotypes (22, 23, and 33) will be termed “APOE-4 
absent”. 
2.1.5 Statistical Analysis 
An a priori significance level of α=0.05 was used to determine statistical significance in 
all tests.  Descriptive statistics were compared for the subgroup of participants who did not have 
MCI at baseline and never developed it during the study, with the subgroup of participants who 
did not have MCI at baseline yet were diagnosed at a later visit.  The distribution of continuous 
independent variables was assessed using the Kolmogorov-Smirnov test of normality.  
Statistically significant differences in characteristics between the 2 subgroups was assessed using 
a Wilcoxon Man-Whitney test on continuous independent variables due to all variables being 
non-normally distributed.  Differences in distribution of categorical variables (race, gender, and 
APOE-4 presence) were assessed using Chi-Squared Tests, and Fishers Exact Test when 
sufficiently small.  A Hardy-Weinberg Equilibrium table displaying genotype and allele 
frequencies based on a 3 allele expansion equation (p2+2pq+q2+2qr+r2) was constructed, using a 
Chi-Squared Test to determine statistical significance.  A Spearman correlation matrix 
containing all independent variables was created to examine any relationship between variables.  
A product limit survival table showing normal cognition/at-risk individuals and MCI diagnosed 
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individuals by visit number was constructed as part of a survival analysis. A Kaplan-Meier 
survival curve was created and stratified by APOE-4 presence and analyzed using a log-rank 
statistic and Chi-Squared Test.  As part of the survival analysis examining time to diagnosis of 
MCI,  Cox proportional hazard regression models were constructed,  censoring for death, 
dementia, dropout, and having <6 of 10 completed neuropsychological tests and/or no CDR.  
Univariate Cox proportional hazard regressions were constructed for age at entry (years), 
education at entry (years), and IQ.  Cox proportional hazard regressions for APOE-4 presence, 
the summary score for frequency of engagement in cognitive reserve behaviors, and the 
summary score for diversity of cognitive reserve behaviors were constructed, adjusting for the 
primary predictors of age at entry (years), education at entry (years), and IQ.  Lastly, a full model 
was constructed incorporating age at entry (years), education at entry (years), IQ, APOE-4 
presence, the summary score for frequency of engagement in cognitive reserve behaviors, and 
the summary score for diversity of cognitive reserve behaviors.  The Akaike Information 
Criterion (AIC) model fit statistic will also be included in the Cox proportional hazard models to 
help assess model fit before and after adjustment.   
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3.0  RESULTS 
Table 1 describes the demographics of the subset of the sample who did not have MCI at 
baseline and never developed it (n=1,226, 53.68%), as well as the individuals who did not have 
MCI at baseline but developed incident MCI later on in the study (n=1,058, 46.32%). 
Independent variables were all non-normally distributed according to the Kolmogorov-Smirnov 
test (p<0.0001). Both groups’ median age upon entry into the study were below 80 but 
significantly differed (p<0.0001). MCI group median quartile age was 77 years (75, 79) and the 
incident MCI group median quartile was 78 years (76, 81). Both groups were predominantly 
Caucasian (97.72% No MCI vs. 95.46% incident MCI) with Black (1.63% vs. 2.46%), 
Asian/Pacific Islander (0.24% vs. 1.23%), and “Other” (0.41% vs. 0.85%) being significantly 
overrepresented in the group developing incident MCI (p=0.008). The distribution of gender 
between groups significantly differed, with a greater proportion of men observed in the incident 
MCI group (52.61% Male No MCI and 56.71% Male incident MCI, p=0.0497). Both groups 
were highly educated. The median number of years of education in both groups was 14 (12, 16 
No MCI and 12, 17 incident MCI) was similar to that of the group developing incident MCI but 
still significantly differed (p=0.0320). The two groups also differed in IQ (p=0.0002), newspaper 
reading frequency (p=0.02), crossword puzzle solving frequency (p=0.03), all being lower 
among incident cases, and APOE-4 presence (p<.0001), with a greater proportion of cases 
carrying at least one APO-4 allele. 
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As shown in Table 2, the genotypic frequency of the entire sample without MCI at 
baseline and the subset who never develop MCI were both in Hardy-Weinberg Equilibrium. This 
examination also revealed that the allele frequency-determined from the genotype frequency of 
the entire sample without MCI at baseline (2=8.03%, 3=79.89%, 4=12.08%) and the subset who 
never develop MCI (2=8.58%, 3=81.08%, 4=10.34%) - were in Hardy Weinberg Equilibrium as 
well. 
Spearman correlations comparing relationships between variables showed several 
significantly associated independent variables in Table 3, though the size of the correlations was 
small. The smallest significant correlation was between IQ and the frequency of taking 
classes/courses (r=0.042, p=0.0428), while the largest correlation was between the frequency of 
using a computer and the frequency of taking classes/courses (r=0.207, p<0.0001). The presence 
of APOE-4 was not significantly correlated with any cognitive reserve behavior. 
A similar Spearman correlation matrix in Table 4 compared the independent variables 
used in the Cox proportional hazards model. Larger significant correlations were seen in this 
table, ranging from (r=-0.045, p=0.029) to (r=0.678, p<0.0001). 
The product limit survival table seen in Table 5 shows that of the group of participants 
who did not have baseline MCI (n=2,284), only 53.93% (n=1,123) remained cognitively normal 
until the end of the study after censoring for death, dementia, dropout, and having <6 
neuropsychological battery tests completed. Incidence rates of MCI were proportionately lowest 
at visit 3 (0.22%) and proportionately highest at visit 9 (8.38%), staying high at visits 10 
(7.36%), 11 (5.495), 12 (7.45%), and 13 (7.85%) until they started to decrease dramatically 
afterwards. The resulting curve in Figure 1 shows the steep decline. The Kaplan Meier survival 
curve stratified by Apoe-4 presence, reveals a better survival (56.2%) in those with no copies of 
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APOE-4 compared to those with at least one copy of APOE-4 (44.47%, log-rank p-value 
<0.0001). 
Univariate Cox proportional hazard models for age at entry (HR=1.098, 95% CI=1.077-
1.120) and IQ (HR=0.985, 95%CI=0.977-0.992) were significant predictors of MCI onset, while 
education was not. Table 6 shows Cox proportional hazard model results for the summary score 
of cognitive reserve behavior frequency, the number of different cognitive reserve behaviors, and 
APOE-4 presence, unadjusted and after adjusting for age at entry, years of education at entry and 
IQ. Neither the unadjusted nor the adjusted models for the summary score of cognitive reserve 
behavior frequency and the number of different cognitive reserve behaviors were significant. 
APOE-4 was a significant predictor of time to MCI onset (HR=1.421, 95%CI=1.220-1.654, 
p<0.0001), becoming larger after adjustment (HR=1.470, 95%CI 1.261-1.713, p=<0.0001). In 
Table 7’s full model of all independent variables, only age at entry, education at entry, IQ, and 
APOE-4 presence were significant predictors of time to MCI onset. 
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4.0  DISCUSSION 
This study examined the association between behaviors comprising cognitive reserve and 
whether or not they affect time to conversion from normal cognition to MCI.  Another aim of 
this study was to examine whether cognitive reserve was associated with the presence of at least 
one copy of APOE-4, and if this genetic factor affected time to conversion from normal 
cognition to MCI as well.  By utilizing the GEM data driven algorithm designed for MCI 
screening at baseline and extending it longitudinally, time to MCI can be determined.  
Significant between group differences were observed in the frequency of reading a 
newspaper and the frequency of solving crossword puzzles in individuals never developing MCI 
versus those who developed incident MCI.  Despite many of the cognitive reserve behaviors 
being correlated to each other, neither the summary score of cognitive reserve behavior 
frequency nor the summary score of cognitive reserve behavior diversity was significant in the 
fully adjusted Cox proportional hazard model. However, it was discovered that IQ, age upon 
study entry, and APOE-4 presence were consistently significant predictors of MCI incidence. In 
the fully adjusted model (Table 7), each unit increase in an individual’s IQ was associated with a 
0.033% reduction in the risk of developing MCI. The fully adjusted Cox proportional hazard 
model also suggested that carrying at least one copy of the APOE-4 gene increased the risk of 
MCI by 44%. Age is likely a very large factor in this disease, as adjustment did not appear to 
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alter its effect on MCI incidence. For each additional year of age, the risk of MCI increased by 
10%. 
Interestingly, the examination of years of education at entry found between group 
differences showed that the incident MCI group was significantly more educated.  Table 7 
supports this finding by showing that as years of education increase, MCI hazard increases (after 
adjusting for IQ, APOE-4 presence, average frequency of cognitive reserve behaviors, and 
number of different cognitive reserve behaviors).  These findings are antithetical to the cognitive 
reserve hypothesis, as previous literature strongly suggests that increasing years of education 
decreases risk of cognitive decline14 and 30.  Further analysis will need to be conducted in order to 
observe why this finding was present, as it is possible that an unaccounted for confounder or bias 
is present, but outside the scope of this study.  One possible explanation may be that a survival 
bias is present.  A study by Meara et al. showed that education is significantly positively 
associated with life expectancy31.  Due to the advanced age (75+ as per GEM protocol) and the 
level of education being high in the sample, it may be that more participants were able to live 
longer, but progressed to MCI as a result of progressive aging. 
Significantly more Black, Asian, and “Other” racially classified individuals were present 
in the incident MCI group than statistically expected, which is consistent with previous studies 
on race/ethnicity and cognitive decline27.  Another expected result was that there appeared to be 
an effect based on sex since a statistically significant proportion of men developed MCI rather 
than their female peers.  This is similar to modern research as it has been shown that in prior 
epidemiological studies, males proportionally develop MCI more often than women28. 
The analysis of genotypes both in the entire subset of individuals without baseline MCI 
and in the subset of the sample who never develop incident MCI showed that the frequencies did 
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not deviate from expected proportions and were in Hardy-Weinberg Equilibrium.  Since it is not 
statistically significant, certain assumptions can be made.  The first assumption is that the quality 
of the actual genotyping was reliably performed, since the allele frequencies roughly match 
background population frequencies29.  The second assumption is that the acquisition of subjects 
upon recruitment and study was sufficiently random and there was no environmental or 
biological selection for a specific allele.  These findings increase the validity of the genetic 
results in the study.   
The product limit survival table allowed for a condensed view of the proportion of the 
sample with normal cognition versus MCI over the course of the study.  No diagnoses were 
made without a CDR, as this was an integral component of the original GEM MCI diagnosis, 
however a total of 11 individuals (8 diagnosed MCI, 3 diagnosed normal) were made with <6 out 
of 10 completed neuropsychological tests.  The protocol for the GEM study at baseline cognitive 
determination mandated that individuals needed to complete ≥6 of 10 neuropsychological tests, 
but did not drop participants over the course of the study for not completing <6 tests at any visit.  
Therefore these 11 individuals who were categorized by the longitudinal application of the GEM 
MCI algorithm were inconsistent with the baseline criteria for MCI versus normal cognition, and 
censored.  It is worth mentioning that the current study is novel in extending the GEM data 
driven algorithm longitudinally.   
The current study has many strengths by borrowing from the GEM data. This study has a 
large sample size enabling ample power for calculations used.  Another strong point this study 
has is the 8 year follow up time, allowing for the novel use of the GEM MCI classification 
algorithm to be applied longitudinally. The algorithmic diagnosis utilized by GEM helps solve 
the issue of inconsistency in MCI diagnosis by systematically using a series of individually 
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validated standardized tests, as well as modifying the impairment cutoff to the lower 10th 
percentile whereas some studies typically use the lower 8th percentile.   Lastly, the pooled data is 
extensive and incorporates detailed information on participant cognition through many different 
validated psychological batteries.   
Limitations of the current study include external validity, effectiveness, and bias 
concerning the GEM data.  Though the recruitment for the GEM study was conducted at 4 
locations- University of Pittsburgh, UC Davis/Sacramento, Johns Hopkins University, and Wake 
Forest University-the sample is both highly educated and overwhelmingly Caucasian, limiting its 
generalizability26.  Secondly, though the GEM MCI classification algorithm’s strength is its 
systematic diagnosis and multi-domain psychological analysis, more data would be needed to 
assess its effectiveness in the general public as a clinical screening tool rather than under 
experimental conditions.  Recall bias may be present, as the LAQ questionnaire that GEM 
subjects participated in prior to enrollment served as the basis for this study’s cognitive reserve 
related behavior frequency variables and was based on participant recall of the prior month25.  
Another limitation of the study occurred due to the GEM study design changing in 2004 to 
include the full neuropsychological battery for every participant annually regardless of 
performance on the 3MSE, CDR, or ADAS-cog, whereas previously the battery was only 
necessary if a participant tripped the preliminary battery3.  For this reason, inclusion of n=303 
cognitively normal subjects at baseline was not possible due to an inability to match multiple 
CDR scores to neuropsychological test scores that did not continue past visit 1.  Further study 
may be necessary, requiring methods to impute missing data.   
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5.0  CONCLUSION 
In summation, this study was not able to observe an association between time to event of 
MCI and the frequency of cognitive reserve behaviors or time to event of MCI and the diversity 
of cognitive reserve behaviors.  Adjusting for the frequency of cognitive reserve behaviors, the 
diversity of cognitive reserve behaviors, APOE-4 presence, IQ, education, and age, higher IQ 
was significantly associated with increased time to MCI, yet increased age, education, and 
APOE-4 presence were significantly associated with decreased time to MCI.  While not part of 
the cognitive reserve hypothesis, the significant effect that age and APOE-4 have on time to MCI 
suggests that individuals 75 years of age and older as well as those with the genetic risk factor of 
APOE-4 may want to be proactive and request more frequent standardized cognitive screening 
similar to the GEM method.  Though IQ is a part of the cognitive reserve hypothesis it is largely 
not modifiable and thus cannot be operationalized to attempt to delay onset of MCI.  Future 
longitudinal studies should seek to determine exactly which modifiable activities comprising the 
cognitive reserve hypothesis are most significant, and systematically test them similar to what 
has been done in this study.  Overall, more research needs to take place on the behavioral, 
neurobiological, and pathological basis of cognitive decline in order to delay the onset of 
cognitive dysfunction in aging.   
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Table 1: Characteristics of Participants without Baseline MCI at Visit 1, N=2,284 
± signifies statistical significance of p<0.05 
Never Develop MCI 
(N=1,226, 53.68%) 
Develop MCI 
(N=1,058, 46.32%) 
Age at entry (Median, 25th percentile, 75th 
percentile ) 
77 (75-79) 78 (76-81)± 
Race 
   White 
   Black 
   Asian/Pacific Islander 
   Other 
N=1,198 (97.72%) 
(N=20, 1.63%) 
(N=3, 0.24%) 
(N=5, 0.41%) 
(N=1,010, 95.46%) 
(N=26, 2.46%) ± 
(N=13, 1.23%) ± 
(N=9, 0.85%) ± 
Gender 
   Male 
   Female 
(N=645, 52.61%) 
(N=581, 47.39%) 
(N=600, 56.71%) ± 
(N=458, 43.29%) 
Education (Median, 25th percentile, 75th percentile )  14(12-16) 14 (12-17)± 
IQ (Median, 25th percentile, 75th percentile ) 120(113-124) 117(111-123)± 
Reading a Book (Median, 25th percentile, 75th 
percentile ) 
10(2.5-30)  10(2.5-30) 
Reading a Newspaper (Median, 25th percentile, 75th 
percentile ) 
30(30-30) 30(10-30)± 
Talking about local/national Issues (Median, 25th 
percentile, 75th percentile ) 
 10(4-30) 10 (2.5-30) 
Crossword Puzzles (Median, 25th percentile, 75th 
percentile ) 
 0(0-10) 0 (0-10)± 
Balancing Checkbook (Median, 25th percentile, 75th 
percentile ) 
 1(1-2.5) 1(1-2.5) 
Taking Courses/Classes (Median, 25th percentile, 
75th percentile ) 
0 (0-0) 0 (0-0) 
Using a Computer (Median, 25th percentile, 75th 
percentile ) 
0 (0-10) 0(0-10) 
APOE-4 Present N=176 (17.76%) N=222 (25.64%) ± 
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Table 2: Distribution of APOE Genotypes and Alleles 
Genotype Frequency Allele 
Frequency 
p= 
22 23 24 33 34 44 2 3 4 
Baseline N=2,074 0.87% 12.25% 2.07% 63.98% 19.58% 1.25% 8.03% 79.89% 12.08% 0.3867 
Never 
MCI 
N=991 0.71% 13.82% 1.92% 65.79% 16.75% 1.01% 8.58% 81.08% 10.34% 0.9829 
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Table 3 Spearman Correlation Matrix, N=2,284 
Bold signifies statistical significance of p<0.05 
IQ Books Newspaper Issues Crossword Checkbook Classes Computer APOE-4 
IQ ____ 0.106 
P=<0.0001 
0.005 
P=0.8268 
0.031 
P=0.1375 
0.066 
P=0.0015 
0.034 
P=0.1006 
0.042 
P=0.0428 
0.121 
P=<0.0001 
-0.032 
P=0.1225 
Books ____ ____ -0.0001 
P=.9982 
0.089 
P=<0.0001 
0.122 
P=0.0014 
0.052 
P=0.0127 
0.060 
P=0.0037 
0.125 
<0.0001 
0.005 
0.8024 
Newspaper ____ ____ ____ 0.218 
P=<0.001 
0.066 
P=<0.0014 
0.027 
P=0.1907 
0.055 
P=0.0084 
0.078 
P=.0002 
0.026 
P=.2037 
Issues ____ ____ ____ ___ 0.022 
P=0.2836 
0.037 
P=0.0782 
0.091 
P=<0.0001 
0.096 
P=<0.0001 
0.025 
P=0.2253 
Crossword ____ ____ ____ ____ ___ 0.047 
P=0.0253 
-0.002 
P=0.9278 
0.039 
P=0.0625 
-0.040 
P=0.0522 
Checkbook ____ ____ ____ ____ ____ 
____ 
0.032 
P=0.1251 
0.066 
P=0.002 
-0.006 
P=.7677 
Classes ____ ____ ____ ____ ____ ____ 
____ 
0.207 
P=<0.0001 
-0.011 
P=0.5850 
Computer ____ ____ ____ ____ ____ ____ ____ 
____ 
-0.025 
P=0.2277 
APOE-4 ____ ____ ____ ____ ____ ____ ____ ____ ____ 
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Table 4: Spearman Correlation Matrix of Cox Model Variables, N=2,284 
IQ APOE-4 Age Education Cognitive Reserve 
Behavior Frequency 
Cognitive Reserve 
Behavior Diversity 
IQ --- -0.032 
p=0.122 
-0.045 
p=0.029 
0.678 
P=<0.000
1 
0.129 
p<0.0001 
0.141 
p<0.0001 
APOE-4 ---- ---------- -0.053 
p=0.011 
-0.002 
p=0.923 
-0.0007 
p=0.975 
-0.037 
p=0.073 
Age ---- ---------- ------ -0.022 
p=0.275 
-0.037 
p=0.075 
-0.049 
p=0.0180 
Education ---- ---------- ------ ------ 0.084 
p<.0001 
0.119 
p<.0001 
Cognitive 
Reserve 
Behavior 
Frequency 
---- ---------- ------ ------ -------------------------- 0.621 
p<.0001 
Cognitive 
Reserve 
Behavior 
Diversity 
---- ---------- ------ ------ -------------------------- ------------------------ 
Bold signifies statistical significance of p<0.05 
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Table 5: Incident MCI by Visit, N=2,284 
Visit Number 
at Risk 
MCI Survival Failure Total 
MCI 
Normal 
Cognition 
# Normal 
Cognition 
With >4 
Missing 
Tests 
# MCI 
With >4 
Missing 
Tests 
3 2,284 5 0.9978 0.00219 5 2,279 0 1 
4 2,278 8 0.9943 0.00569 13 2,270 0 0 
5 2,270 12 0.9891 0.0109 25 2,258 0 0 
6 2,258 18 0.9812 0.0188 43 2,240 0 0 
7 2,240 33 0.9667 0.0333 76 2,207 0 0 
8 2,207 143 0.9041 0.0959 219 2,064 0 0 
9 2,064 173 0.8283 0.1717 392 1,891 0 3 
10 1,888 139 0.7673 0.2327 531 1,749 0 2 
11 1,747 96 0.7252 0.2748 627 1,651 0 0 
12 1,651 123 0.6711 0.3289 750 1,528 0 0 
13 1,528 120 0.6184 0.3816 870 1,408 0 1 
14 1,407 80 0.5833 0.4167 950 1,327 0 0 
15 1,327 63 0.5556 0.4444 1013 1,264 0 1 
16 1,263 37 0.5393 0.4607 1050 1,223 3 0 
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Table 6: Cox Proportional Hazard Models 1-6 
Predictor HR 95% CI P= 
Model 1 Cognitive 
Reserve Behavior 
Frequency 
0.992 0.977- 1.007 0.2827 
Unadjusted AIC= 11836.905 
Model 2 
(Adjusted for age, education, and IQ) 
Cognitive 
Reserve Behavior 
Frequency 
0.999 0.984- 1.015 0.9013 
Adjusted AIC= 11838.674 
Model 3 Cognitive 
Reserve Behavior 
Diversity 
0.986 0.929-1.045 0.6300 
Unadjusted: AIC= 11836.905 
Model 4 
(Adjusted for age, education, and IQ) 
Cognitive 
Reserve Behavior 
Diversity 
1.002 0.943-1.064 0.9518 
Adjusted: AIC=11687.611 
Model 5± Apoe-4 
Presence 
1.421 1.220-1.654 <0.0001 
Unadjusted: AIC=12648.344 
Model 6± 
(Adjusted for age, education, and IQ) 
Apoe-4 
Presence 
1.470 1.261-1.713 <0.0001 
Adjusted: AIC=12466.997 
24 
Table 7: Cox Proportional Hazard Model 7 
Model 7 
Hazard 
Ratio 
95% CI P= 
Age 1.100 1.077-1.123 <.0001 
Education 1.084 1.049-1.120 <.0001 
IQ 0.967 0.957-0.978 <.0001 
APOE4 E4 
Present 
1.441 1.229-1.690 <.0001 
Cognitive 
Reserve 
Behavior 
Frequency 
0.996 0.976-1.015 0.6662 
Cognitive 
Reserve 
Behavior 
Diversity 
1.011 0.937-1.091 0.7809 
AIC 11548.413 
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APPENDIX: FIGURES 
26 
Figure 1: Product Limit Survival Curve of normal cognition visits 3-16 
27 
Figure 2: Kaplan Meier Survival Curve stratified by APOE-4 Presence for visits 3-16 
28 
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